JP7096249B2 - dsRNAを標的化するためのキメラタンパク質 - Google Patents
dsRNAを標的化するためのキメラタンパク質 Download PDFInfo
- Publication number
- JP7096249B2 JP7096249B2 JP2019533723A JP2019533723A JP7096249B2 JP 7096249 B2 JP7096249 B2 JP 7096249B2 JP 2019533723 A JP2019533723 A JP 2019533723A JP 2019533723 A JP2019533723 A JP 2019533723A JP 7096249 B2 JP7096249 B2 JP 7096249B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- scp
- dsrb
- gfp
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022048101A JP2022104932A (ja) | 2016-09-04 | 2022-03-24 | dsRNAを標的化するためのキメラタンパク質 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383466P | 2016-09-04 | 2016-09-04 | |
US62/383,466 | 2016-09-04 | ||
PCT/IL2016/051341 WO2018042411A1 (en) | 2016-09-04 | 2016-12-15 | Chimeric proteins for targeting dsrna |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022048101A Division JP2022104932A (ja) | 2016-09-04 | 2022-03-24 | dsRNAを標的化するためのキメラタンパク質 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019534037A JP2019534037A (ja) | 2019-11-28 |
JP7096249B2 true JP7096249B2 (ja) | 2022-07-05 |
Family
ID=61300251
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019533723A Active JP7096249B2 (ja) | 2016-09-04 | 2016-12-15 | dsRNAを標的化するためのキメラタンパク質 |
JP2022048101A Pending JP2022104932A (ja) | 2016-09-04 | 2022-03-24 | dsRNAを標的化するためのキメラタンパク質 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022048101A Pending JP2022104932A (ja) | 2016-09-04 | 2022-03-24 | dsRNAを標的化するためのキメラタンパク質 |
Country Status (8)
Country | Link |
---|---|
US (3) | US11912747B2 (zh) |
EP (1) | EP3507308A4 (zh) |
JP (2) | JP7096249B2 (zh) |
CN (1) | CN109790225B (zh) |
AU (1) | AU2016421686A1 (zh) |
BR (1) | BR112019004017A2 (zh) |
CA (1) | CA3034989A1 (zh) |
WO (1) | WO2018042411A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109790225B (zh) | 2016-09-04 | 2022-09-09 | 塔尔格免疫治疗有限公司 | 用于靶向dsRNA的嵌合蛋白 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532017A (ja) | 2006-02-10 | 2009-09-10 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | PTD/CPPSへのdsRNA結合ドメイン融合体によるsiRNAの導入可能な送達 |
JP2012513210A (ja) | 2008-12-22 | 2012-06-14 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー | 全身的な癌処置のためのegfrホーミング二本鎖rnaベクター |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03010804A (es) * | 2001-06-01 | 2004-11-22 | Cornell Res Foundation Inc | Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos. |
SG158154A1 (en) * | 2004-12-29 | 2010-01-29 | Mannkind Corp | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
CA2695385A1 (en) * | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
US20150174265A1 (en) | 2012-06-26 | 2015-06-25 | Massachusetts Institute Of Technology | Reversible masking of pore-forming proteins for macromolecular delivery |
CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9809632B2 (en) * | 2013-10-23 | 2017-11-07 | University Of Washington Through Its Center For Commercialization | Universal protein tag for double stranded nucleic acid delivery |
SG10201911695SA (en) | 2014-05-14 | 2020-01-30 | Targimmune Therapeutics Ag | Improved polyethyleneimine polyethyleneglycol vectors |
ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
CN109790225B (zh) | 2016-09-04 | 2022-09-09 | 塔尔格免疫治疗有限公司 | 用于靶向dsRNA的嵌合蛋白 |
-
2016
- 2016-12-15 CN CN201680088934.2A patent/CN109790225B/zh active Active
- 2016-12-15 BR BR112019004017A patent/BR112019004017A2/pt active Search and Examination
- 2016-12-15 CA CA3034989A patent/CA3034989A1/en active Pending
- 2016-12-15 US US16/329,577 patent/US11912747B2/en active Active
- 2016-12-15 JP JP2019533723A patent/JP7096249B2/ja active Active
- 2016-12-15 WO PCT/IL2016/051341 patent/WO2018042411A1/en active Application Filing
- 2016-12-15 EP EP16915025.7A patent/EP3507308A4/en active Pending
- 2016-12-15 AU AU2016421686A patent/AU2016421686A1/en active Pending
-
2018
- 2018-03-08 US US15/915,770 patent/US11230580B2/en active Active
-
2022
- 2022-01-24 US US17/582,160 patent/US20220213158A1/en active Pending
- 2022-03-24 JP JP2022048101A patent/JP2022104932A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532017A (ja) | 2006-02-10 | 2009-09-10 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | PTD/CPPSへのdsRNA結合ドメイン融合体によるsiRNAの導入可能な送達 |
JP2012513210A (ja) | 2008-12-22 | 2012-06-14 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー | 全身的な癌処置のためのegfrホーミング二本鎖rnaベクター |
Non-Patent Citations (3)
Title |
---|
EIF2AK2 protein,GenBank[online], AAH22314.1,2007年09月11日,https://www.ncbi.nlm.nih.gov/protein/aah22314,[retrieved on 11.24.2020] |
Langut, Y. et al.,NOVEL TARGETED THERAPY FOR PROSTATE CANCER,The fifth annual meeting of the Israeli society for cancer research (ISCR),2013年,https://program.eventact.com/Agenda/Lecture/36480?code=1040194,[retrieved on 11.12.2020] |
Ultimo, A. et al.,Targeting Innate Immunity with dsRNA-Conjugated Mesoporous Silica Nanoparticles Promotes Antitumor Effects on Breast Cancer Cells,Chemistry - European Journal,2016年01月07日,Vol. 22(5),pp. 1582-1586 |
Also Published As
Publication number | Publication date |
---|---|
JP2019534037A (ja) | 2019-11-28 |
CA3034989A1 (en) | 2018-03-08 |
RU2019104180A (ru) | 2020-10-05 |
CN109790225A (zh) | 2019-05-21 |
BR112019004017A2 (pt) | 2019-06-25 |
US20220213158A1 (en) | 2022-07-07 |
JP2022104932A (ja) | 2022-07-12 |
US11912747B2 (en) | 2024-02-27 |
EP3507308A1 (en) | 2019-07-10 |
RU2019104180A3 (zh) | 2021-06-24 |
CN109790225B (zh) | 2022-09-09 |
US20190194282A1 (en) | 2019-06-27 |
US11230580B2 (en) | 2022-01-25 |
EP3507308A4 (en) | 2020-03-18 |
AU2016421686A1 (en) | 2019-04-04 |
WO2018042411A1 (en) | 2018-03-08 |
US20180346596A1 (en) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7403521B2 (ja) | セリンプロテアーゼ分子および療法 | |
Arafiles et al. | Stimulating macropinocytosis for intracellular nucleic acid and protein delivery: A combined strategy with membrane-lytic peptides to facilitate endosomal escape | |
JP2020010701A (ja) | インターロイキン−4受容体結合融合タンパク質及びその使用 | |
KR20230074076A (ko) | 개질된 미토콘드리아 및 이의 용도 | |
JP5114418B2 (ja) | 細胞死を抑制する又は細胞増殖を高めるための方法及び組成物 | |
WO2017039382A1 (ko) | 인간 유래 페리틴 모노머 단편 및 이를 이용한 융합폴리펩티드 | |
CA3017717A1 (en) | Use of pten-long leader sequence for transmembrane delivery of molecules | |
Watson et al. | Shortened penetratin cell-penetrating peptide is insufficient for cytosolic delivery of a Grb7 targeting peptide | |
JP2013535954A (ja) | ペプチド、構造体およびその使用 | |
EP3041860B1 (en) | Semaphorin 3c variants, compositions comprising said variants and methods of use thereof | |
JP2007527856A (ja) | 癌細胞を選択的に死滅させるRasGAP由来ペプチド | |
JP2022104932A (ja) | dsRNAを標的化するためのキメラタンパク質 | |
Yang et al. | A Versatile Platform for the Tumor‐Targeted Intracellular Delivery of Peptides, Proteins, and siRNA | |
EP2182068A1 (en) | Use of bacteria for the sensing and killing of cancer cells | |
RU2806285C2 (ru) | ХИМЕРНЫЕ БЕЛКИ ДЛЯ НАЦЕЛИВАНИЯ дцРНК | |
Wang et al. | Construction of human LRIG1-TAT fusions and TAT-mediated LRIG1 protein delivery | |
CN101684159A (zh) | 人颗粒酶b蛋白衍生物及其在靶向治疗腺癌中的用途 | |
DK2257299T3 (en) | Modulation of SRPX2-mediated angiogenesis | |
US10125183B2 (en) | Decoy peptides inhibiting binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 | |
Wei et al. | Novel Oxygen-Dependent Degradable Immunotoxin Regulated by the Ubiquitin–Proteasome System Reduces Nonspecific Cytotoxicity | |
KR101208994B1 (ko) | 세포 투과성 rpS3 융합 단백질을 포함하는 염증 예방 및 치료용 조성물 | |
JP2021534826A (ja) | がんの処置のためのペプチド治療薬およびその使用 | |
Winkles et al. | GrB TWEAK: A Potential Novel Biologic for NSCLC Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191209 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210601 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220324 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220324 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220411 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220428 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220510 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220614 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220623 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7096249 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |